{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:46:28Z","timestamp":1772804788430,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T00:00:00Z","timestamp":1522022400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Ministry of Health and Labour Sciences Research Grants of Japan for Research on Rare and Intractable Diseases"},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s10384-018-0589-2","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T07:29:57Z","timestamp":1522049397000},"page":"390-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of efficacy of infliximab for retinal vasculitis and extraocular symptoms in Beh\u00e7et disease"],"prefix":"10.1007","volume":"62","author":[{"given":"Akihiko","family":"Umazume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kezuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,26]]},"reference":[{"key":"589_CR1","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","volume":"130","author":"AA Okada","year":"2012","unstructured":"Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease. Arch Ophthalmol. 2012;130:592\u20138.","journal-title":"Arch Ophthalmol"},{"key":"589_CR2","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","volume":"121","author":"M Takeuchi","year":"2014","unstructured":"Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et\u2019s disease: a multicenter study. Ophthalmology. 2014;121:1877\u201384.","journal-title":"Ophthalmology"},{"key":"589_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374.","journal-title":"J Autoimmun"},{"issue":"786\u201396","key":"589_CR4","first-page":"e3","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(786\u201396):e3.","journal-title":"Ophthalmology"},{"key":"589_CR5","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1002\/art.22214","volume":"54","author":"K Bendtzen","year":"2006","unstructured":"Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheumatol. 2006;54:3782\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"589_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/bjo.2009.174888","volume":"95","author":"S Sugita","year":"2011","unstructured":"Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Beh\u00e7et disease. Br J Ophthalmol. 2011;95:549\u201352.","journal-title":"Br J Ophthalmol"},{"key":"589_CR7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00417-011-1908-1","volume":"250","author":"D Iwata","year":"2012","unstructured":"Iwata D, Namba K, Mizuuchi K, Kitaichi N, Kase S, Takemoto Y, et al. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Beh\u00e7et\u2019s disease with infliximab. Graefes Arch Clin Exp Ophthalmol. 2012;250:1081\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"589_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheumatol. 1995;38:44\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"589_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10384-013-0294-0","volume":"58","author":"T Kaburaki","year":"2014","unstructured":"Kaburaki T, Namba K, Sonoda K, Kezuka T, Keino H, Fukuhara T, et al. Beh\u00e7et\u2019s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58:120\u201330.","journal-title":"Jpn J Ophthalmol"},{"key":"589_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","volume":"27","author":"CM Deuter","year":"2008","unstructured":"Deuter CM, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M. Beh\u00e7et\u2019s disease: ocular effects and treatment. Prog Retin Eye Res. 2008;27:111\u201336.","journal-title":"Prog Retin Eye Res"},{"key":"589_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","volume":"50","author":"C Evereklioglu","year":"2005","unstructured":"Evereklioglu C. Current concepts in the etiology and treatment of Beh\u00e7et disease. Surv Ophthalmol. 2005;50:297\u2013350.","journal-title":"Surv Ophthalmol"},{"key":"589_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1177\/112067210201200514","volume":"12","author":"PC Ozdal","year":"2002","unstructured":"Ozdal PC, Ortac S, Taskintuna I, Firat E. Posterior segment involvement in ocular Beh\u00e7et\u2019s disease. Eur J Ophthalmol. 2002;12:424\u201331.","journal-title":"Eur J Ophthalmol"},{"key":"589_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00417-005-0005-8","volume":"243","author":"M Takeuchi","year":"2005","unstructured":"Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, et al. Risk and prognostic factors of poor visual outcome in Beh\u00e7et\u2019s disease with ocular involvement Graefes. Arch Clin Exp Ophthalmol. 2005;243:1147\u201352.","journal-title":"Arch Clin Exp Ophthalmol"},{"key":"589_CR14","first-page":"1078","volume":"335","author":"No author listed","year":"1990","unstructured":"No author listed. Criteria for diagnosis of Behcet\u2019s disease. International Study Group for Behcet\u2019s Disease. Lancet. 1990;335:1078\u201380.","journal-title":"Lancet"},{"key":"589_CR15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3349\/ymj.2015.56.4.1087","volume":"56","author":"M Kim","year":"2015","unstructured":"Kim M, Kwon HJ, Choi EY, Kim SS, Koh HJ, Lee SC. Correlation between fluorescein angiographic findings and visual acuity in Beh\u00e7et retinal vasculitis. Yonsei Med J. 2015;56:1087\u201396.","journal-title":"Yonsei Med J"},{"key":"589_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00417-014-2637-z","volume":"252","author":"HM Kang","year":"2014","unstructured":"Kang HM, Lee SC. Long-term progression of retinal vasculitis in Beh\u00e7et patients using a fluorescein angiography scoring system. Graefes Arch Clin Exp Ophthalmol. 2014;252:1001\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"589_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10792-013-9788-5","volume":"34","author":"M Mesquida","year":"2014","unstructured":"Mesquida M, Molins B, Llorenc V, Hernandez MV, Espinosa G, Dick AD, et al. Current and future treatments for Beh\u00e7et\u2019s uveitis: road to remission. Int Ophthalmol. 2014;34:365\u201381.","journal-title":"Int Ophthalmol"},{"key":"589_CR18","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1136\/bjo.87.12.1466","volume":"87","author":"LS Atmaca","year":"2003","unstructured":"Atmaca LS, Sonmez PA. Fluorescein and indocyanine green angiography findings in Beh\u00e7et\u2019s disease. Br J Ophthalmol. 2003;87:1466\u20138.","journal-title":"Br J Ophthalmol"},{"key":"589_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/09273940490518757","volume":"13","author":"S Gedik","year":"2005","unstructured":"Gedik S, Akova Y, Yilmaz G, Bozbeyoglu S. Indocyanine green and fundus fluorescein angiographic findings in patients with active ocular Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm. 2005;13:51\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"589_CR20","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/eye.2014.138","volume":"28","author":"H Keino","year":"2014","unstructured":"Keino H, Okada AA, Watanabe T, Taki W. Long-term efficacy of infliximab on background vascular leakage in patients with Beh\u00e7et\u2019s disease. Eye (Lond). 2014;28:1100\u20136.","journal-title":"Eye (Lond)"},{"key":"589_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.oftal.2014.03.016","volume":"90","author":"P Baneros-Rojas","year":"2015","unstructured":"Baneros-Rojas P, Berrozpe-Villabona C, Peraza-Nieves JE, Diaz-Valle D. Early treatment with infliximab in bilateral occlusive vasculitis as a presenting manifestation of Beh\u00e7et\u2019 disease. Arch Soc Esp Oftalmol. 2015;90:285\u20138.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"589_CR22","first-page":"73","volume-title":"Understanding Fluorescein Angiography","author":"M Spitznas","year":"2006","unstructured":"Spitznas M. Understanding Fluorescein Angiography. Berlin: Springer; 2006. p. 73\u201399."},{"key":"589_CR23","first-page":"42","volume-title":"Uveitis: Fundamentals and Clinical Practice","author":"R Nussenblatt","year":"2010","unstructured":"Nussenblatt R. Uveitis: Fundamentals and Clinical Practice. 4th ed. Philadelphia: Elsevier; 2010. p. 42\u201371.","edition":"4"},{"key":"589_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.oftal.2014.03.016","volume":"90","author":"P Baneros-Rojas","year":"2015","unstructured":"Baneros-Rojas P, Berrozpe-Villabona C, Peraza-Nieves JE, Diaz-Valle D. Early treatment with infliximab in bilateral occlusive vasculitis as a presenting manifestation of Beh\u00e7et\u2019 disease. Arch Soc Esp Oftalmol. 2015;90:285\u20138.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"589_CR25","doi-asserted-by":"publisher","first-page":"R545","DOI":"10.1186\/ar1715","volume":"7","author":"M Bandt De","year":"2005","unstructured":"De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545\u201351.","journal-title":"Arthritis Res Ther"},{"key":"589_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.homp.2016.09.002","volume":"105","author":"MZ Teixeira","year":"2016","unstructured":"Teixeira MZ. Biological therapies (immunomodulatory drugs), worsening of psoriasis and rebound effect: new evidence of similitude. Homeopathy. 2016;105:344\u201355.","journal-title":"Homeopathy"},{"key":"589_CR27","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1136\/annrheumdis-2011-200945","volume":"71","author":"A Maas van der","year":"2012","unstructured":"van der Maas A, Kievit W, van den Bemt BJ, van den Hoogen FH, van Riel PL, den Broeder AA. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012;71:1849\u201354.","journal-title":"Ann Rheum Dis"},{"key":"589_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/ard.2010.136556","volume":"70","author":"NB Klarenbeek","year":"2011","unstructured":"Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, van Groenendael JH, Han KH, Kerstens PJ, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis. 2011;70:315\u20139.","journal-title":"Ann Rheum Dis"},{"key":"589_CR29","first-page":"1021","volume":"20","author":"P Molander","year":"2014","unstructured":"Molander P, Farkkila M, Salminen K, Kemppainen H, Blomster T, Koskela R, et al. Outcome after discontinuation of TNFalpha-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis. 2014;20:1021\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"589_CR30","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.clinthera.2013.10.008","volume":"38","author":"Y Tanaka","year":"2013","unstructured":"Tanaka Y, Hirata S. Is it possible to withdraw biologics from therapy in rheumatoid arthritis. Clin Ther. 2013;38:2028\u201335.","journal-title":"Clin Ther"},{"key":"589_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jaad.2015.04.023","volume":"73","author":"WB Kim","year":"2015","unstructured":"Kim WB, Marinas JE, Qiang J, Shahbaz A, Greaves S, Yeung J. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: a Canadian multicenter retrospective study. J Am Acad Dermatol. 2015;73:237\u201341.","journal-title":"J Am Acad Dermatol"},{"key":"589_CR32","doi-asserted-by":"publisher","first-page":"e005615","DOI":"10.1136\/bmjopen-2014-005615","volume":"4","author":"T Nakashita","year":"2014","unstructured":"Nakashita T, Ando K, Kaneko N, Takahashi K, Motojima S. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014;4:e005615.","journal-title":"BMJ Open"},{"key":"589_CR33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cgh.2007.02.016","volume":"5","author":"RA Hansen","year":"2007","unstructured":"Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5:729\u201335.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"589_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10384-013-0283-3","volume":"58","author":"T Kawaguchi","year":"2014","unstructured":"Kawaguchi T, Kawazoe Y, Kamoi K, Miyanaga M, Takase H, Sugita S, et al. Clinical course of patients with Beh\u00e7et\u2019s uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol. 2014;58:75\u201380.","journal-title":"Jpn J Ophthalmol"},{"key":"589_CR35","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3109\/09273948.2013.779727","volume":"21","author":"S Al Rashidi","year":"2013","unstructured":"Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Long-term clinical outcomes in patients with refractory uveitis associated with Beh\u00e7et disease treated with infliximab. Ocul Immunol Inflamm. 2013;21:468\u201374.","journal-title":"Ocul Immunol Inflamm"},{"key":"589_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10792-010-9372-1","volume":"30","author":"A Adan","year":"2010","unstructured":"Adan A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Beh\u00e7et\u2019s disease after withdrawal of infusions. Int Ophthalmol. 2010;30:577\u201381.","journal-title":"Int Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-018-0589-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-018-0589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-018-0589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T05:49:30Z","timestamp":1589867370000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-018-0589-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,26]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1007\/s10384-018-0589-2","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,26]]},"assertion":[{"value":"24 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A. Umazume, None; T. Kezuka, Grant (Mitsubishi Tanabe Pharma), Lecture fee (Mitsubishi Tanabe Pharma); Y. Usui, None; J. Suzuki, None; H. Goto, Grant (Mitsubishi Tanabe Pharma), Lecture fee (Mitsubishi Tanabe Pharma).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}